Results 201 to 210 of about 35,703 (223)
Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care? [PDF]
Curr Cardiol RepBrandts J, Marx N.
europepmc +1 more source
Refined Design and Liquid-Phase Assembly of GalNAc-siRNA Conjugates: Comparative Efficiency Validation in PCSK9 Targeting. [PDF]
MoleculesDmitriev NA +8 more
europepmc +1 more source
Reduced Serum Soluble L-Selectin Levels but Not PCSK9 May Be Associated With Generalized Anxiety Disorder: A Case-Control Study. [PDF]
J Clin Lab AnalMunny FA +7 more
europepmc +1 more source
Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis. [PDF]
Int J Cardiol Cardiovasc Risk PrevDing W, Sun L, Shi Y, Tian L.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Lipidology, 2013
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire +2 more sources
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire +2 more sources
Understanding PCSK9 and anti-PCSK9 therapies
Journal of Clinical Lipidology, 2015Inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) represent a new therapeutic category of drugs for the treatment of dyslipidemia and atherosclerotic cardiovascular disease. To appreciate the efficacy of these agents and interpret research results, it is important to understand the dynamic relationship between PCSK9, low-density ...
openaire +2 more sources
Metabolic impact of extrahepatic PCSK9 modulation: Extrahepatic PCSK9 modulation
European Atherosclerosis Journal, 2022The Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) protease is a 692 amino acid glycoprotein which belongs to the proprotein convertase family. PCSK9 binds several receptors of the LDL family, including VLDLR, LRP1 but also with CD36, driving their lysosomal degradation.
Da Dalt, Lorenzo, Bonacina, Fabrizia
openaire +1 more source
Current Atherosclerosis Reports
In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.The success of PCSK9 inhibition with monoclonal antibody injections has fueled the development of additional therapies targeting PCSK9, including oral formulations ...
Anandita, Agarwala +2 more
openaire +2 more sources
In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.The success of PCSK9 inhibition with monoclonal antibody injections has fueled the development of additional therapies targeting PCSK9, including oral formulations ...
Anandita, Agarwala +2 more
openaire +2 more sources
Antihyperlipidemic Therapies Targeting PCSK9
Cardiology in Review, 2014Hyperlipidemia is a major cause of cardiovascular disease despite the availability of first-line cholesterol-lowering agents such as statins. A new therapeutic approach to lowering low-density lipoprotein-cholesterol (LDL-C) acts by blocking LDL-receptor degradation by serum proprotein convertase subtilisin kexin 9 (PCSK9).
Michael, Weinreich, William H, Frishman
openaire +2 more sources